The Aidaptus ® disposable auto-injector platform, designed by Owen Mumford, will be jointly offered to global biopharma companies to support their drug development programs with engineering and ...

Stevanato has added another drug delivery technology to its portfolio, teaming up with Owen Mumford to provide customers with a two-step, single-use auto-injector that automatically adapts to a range ...

The acquisition positions Embecta to enter the fast-growing drug-delivery device market and accelerate its shift to a broader medical supplies company. Adds a differentiated drug-delivery platform ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Embecta Corp. EMBC recently announced a definitive agreement to acquire Owen Mumford Holdings Limited, a pioneer in developing advanced drug delivery systems and medical device solutions, making a ...

Stevanato Group’s integrated offering addressing mAbs challenges includes Aidaptus®, a 2-step single-use auto-injector accommodating 1mL and 2.25mL PFSs in the same base device, supporting a range of ...

Acquisition will position embecta to participate in the rapidly expanding market for drug-delivery devices supporting generic and branded therapies and accelerate transformation into a broad‑based ...

PARSIPPANY, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta”) (Nasdaq: EMBC), a global leader in diabetes care technology, today announced that it has completed its previously announced ...

An announcement from Embecta Corporation ( (EMBC)) is now available. On March 19, 2026, Embecta announced a definitive agreement to acquire privately held U.K. medical device maker Owen Mumford ...

PARSIPPANY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“Embecta”) (Nasdaq: EMBC), a global leader in diabetes care technology, today announced that it has entered into a definitive ...